The effect of the alpha-emitting radionuclide lead-212 on human ovarian carcinoma: a potential new form of therapy.
To improve response and survival of patients with ovarian carcinoma noncross-resistant forms of therapy must be developed. alpha-emitting radionuclides may be therapeutically useful since they can directly ionize with energies of 5 to 9 MeV, penetrate only a few cell diameters, and transfer a high amount of energy. The purpose of this study was to determine the effect of the alpha-emitter, lead-212 (212Pb), complexed to sulfur in a nude athymic mouse model (NIH:OVCAR-3) containing human ascites and solid epithelial ovarian carcinoma. Thirty-six nude mice 28 to 32 days old were injected with 10(7) to 10(8) carcinoma cells from donor mice. After 4 weeks, six groups of six nu/nu athymic BALB-C mice were intraperitoneally injected with 70, 50, 20, 5 microCi of 212Pb sulfur colloid, sulfur colloid, or saline. Tumor necrosis with a decrease in ascites and a dose-related survival were noted with doses of 50, 20, and 5 microCi. With 70 microCi acute gastrointestinal toxicity developed. These experiments form the basis for further investigations and the development of alpha-emitting radiocolloids which may be of therapeutic efficacy in the treatment of intraperitoneal ovarian carcinoma.
Rotmensch
J
J
Department of Obstetrics and Gynecology, University of Chicago, Pritzker School of Medicine, Illinois 60637.
Atcher
R W
RW
Schlenker
R
R
Hines
J
J
Grdina
D
D
Block
B S
BS
Press
M F
MF
Herbst
A L
AL
Weichselbaum
R R
RR
D000818:Animals; D005260:Female; D006801:Humans; D007856:Lead Radioisotopes / Q000627:therapeutic use*; D051379:Mice; D008807:Mice, Inbred BALB C; D010051:Ovarian Neoplasms / Q000532:radiotherapy*; D051381:Rats; D011919:Rats, Inbred Strains
D007856:Lead Radioisotopes